417 related articles for article (PubMed ID: 19829109)
1. Combination therapy of statins and fibrates in the management of cardiovascular risk.
Fiévet C; Staels B
Curr Opin Lipidol; 2009 Dec; 20(6):505-11. PubMed ID: 19829109
[TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
4. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
[TBL] [Abstract][Full Text] [Related]
5. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
6. Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Brinton EA
Curr Atheroscler Rep; 2008 Feb; 10(1):25-32. PubMed ID: 18366982
[TBL] [Abstract][Full Text] [Related]
7. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M
Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
Robins SJ
Curr Opin Lipidol; 2003 Dec; 14(6):575-83. PubMed ID: 14624134
[TBL] [Abstract][Full Text] [Related]
9. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
Devroey D; Velkeniers B; Duquet W; Betz W
Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669
[TBL] [Abstract][Full Text] [Related]
10. [Lipid therapy in patients with diabetes].
Saely CH; Drexel H
Wien Med Wochenschr; 2010 Jan; 160(1-2):25-9. PubMed ID: 20229158
[TBL] [Abstract][Full Text] [Related]
11. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
12. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
13. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
Sharma RK; Singh VN; Reddy HK
Vasc Health Risk Manag; 2009; 5():793-9. PubMed ID: 19812691
[TBL] [Abstract][Full Text] [Related]
14. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
15. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
16. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
[TBL] [Abstract][Full Text] [Related]
17. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
18. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
19. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention.
Chapman MJ
Cardiovasc Drugs Ther; 2005 Mar; 19(2):135-9. PubMed ID: 16025232
[TBL] [Abstract][Full Text] [Related]
20. Fibrates in combination with statins in the management of dyslipidemia.
Jacobson TA; Zimmerman FH
J Clin Hypertens (Greenwich); 2006 Jan; 8(1):35-41; quiz 42-3. PubMed ID: 16407687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
